Presbyopia Treatments

Find Presbyopia Treatments

Generic Name

Hydrchloride

Brand Names

Salagen, VUITY, Qlosi

FDA approval date: October 14, 2005

Classification: Cholinergic Receptor Agonist

Form: Tablet, Solution

What is Salagen (Hydrchloride)?

Pilocarpine hydrochloride tablets, USP are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)

Enrollment Status: Recruiting

Publish Date: January 09, 2026

Intervention Type: Device, Other

Study Phase: Not Applicable

Summary: Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of limitations. The objectives of this study are: 1)To evaluate a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels as a potential low-cost but...

A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade Surgery

Who is this study for: Patients with Glaucoma

Enrollment Status: Recruiting

Publish Date: November 10, 2025

Intervention Type: Drug

Study Drugs: Pilocarpine, Prednisolone, Ofloxacin

Study Phase: Phase 3

Summary: The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + Kahook Dual Blade (KDB) surgery.

Understanding Quality of Life in Presbyopic Patients Who Are Treated With Qlosi

Enrollment Status: Recruiting

Publish Date: August 12, 2025

Intervention Type: Drug

Study Phase: Phase 4

Summary: The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments * Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (conti...

View All Clinical Trials